Evidence map›Paper›PMID 28151412›Full record

Trial reportJournal of the American Society of Nephrology : JASN2017

A Trial of Extending Hemodialysis Hours and Quality of Life.

Meg J Jardine, Li Zuo, Nicholas A Gray, Janak R de Zoysa, Christopher T Chan, Martin P Gallagher, Helen Monaghan, Stuart M Grieve, Rajesh Puranik, Hongli Lin and 9 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00649298 (ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease.), which is not on this map. Cited by 28 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 8 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00649298 phase4completednot on this map

ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease.

TypeinterventionalSponsorThe George InstituteRan2008 to 2014Enrolled200ConditionsRenal Replacement Therapy, Renal Dialysis, End Stage Kidney Disease, End Stage Renal DiseaseArmshaemodialysis
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 8 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Guideline
  2. Home versus in-centre haemodialysis for people with kidney failure.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Patient Preferences for Longer or More Frequent In-Center Hemodialysis Regimens: A Multicenter Discrete Choice Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 7 countries.

Meg J JardineThe George Institute for Global Health, mjardine@georgeinstitute.org.au.
Li ZuoDepartment of Nephrology, Peking University People's Hospital, Beijing, China.
Nicholas A GrayDepartment of Renal Medicine, Nambour General Hospital, Nambour, Australia.
Janak R de ZoysaDepartment of Nephrology, North Shore Hospital, University of Auckland, Auckland, New Zealand.
Christopher T ChanDivision of Nephrology, University Health Network, Toronto, Canada.
Martin P GallagherThe George Institute for Global Health.
Helen MonaghanThe George Institute for Global Health.
Stuart M GrieveSydney Translational Imaging Laboratory, Charles Perkins Centre, Sydney Medical School, and.
Rajesh PuranikSunshine Coast Clinical School, The University of Queensland, Brisbane, Australia.
Hongli LinFirst Affiliated Hospital of Dalian Medical University, Dalian, China.
Josette M ErisDepartment of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
Ling ZhangDepartment of Nephrology, China-Japan Friendship Hospital, Beijing, China.
Jinsheng XuFourth Hospital Affiliated to Hebei Medical University, Shijiazhuang, China.
Kirsten HowardSchool of Public Health, University of Sydney, Sydney, Australia.
Serigne LoThe George Institute for Global Health.
Alan CassMenzies School of Health Research, Charles Darwin University, Darwin, Australia; and.
Vlado PerkovicThe George Institute for Global Health.
ACTIVE Dialysis Steering Committee
Paul
The George Institute for Global Health · GBRoyal North Shore Hospital · AUThe University of Queensland · AUChina-Japan Friendship Hospital · CNConcord Hospital · USConcord Repatriation General Hospital · AUHebei Medical University · CNMenzies School of Health Research · AUNambour General Hospital · AUPeking University · CNThe University of Sydney · AUUniversity Health Network · CAUniversity of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between increased hemodialysis hours and patient outcomes remains unclear. We randomized (1:1) 200 adult recipients of standard maintenance hemodialysis from in-center and home-based hemodialysis programs to extended weekly (≥24 hours) or standard (target 12-15 hours, maximum 18 hours) hemodialysis hours for 12 months. The primary outcome was change in quality of life from baseline assessed by the EuroQol 5 dimension instrument (3 level) (EQ-5D). Secondary outcomes included medication usage, clinical laboratory values, vascular access events, and change in left ventricular mass index. At 12 months, median weekly hemodialysis hours were 24.0 (interquartile range, 23.6-24.0) and 12.0 (interquartile range, 12.0-16.0) in the extended and standard groups, respectively. Change in EQ-5D score at study end did not differ between groups (mean difference, 0.04 [95% confidence interval, -0.03 to 0.11];

Indexed as

Quality of LifeFemaleHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesRenal DialysisTime Factorsextended dialysishemodialysisleft ventricular hypertrophyquality of liferandomized controlled trials

Identifiers

PMID28151412
PMCPMC5461782
OpenAlexW2585600138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.